Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CytoDyn, Inc.
Social Media: Use Of Influencers In Drug Promotion Requires Guardrails, Experts Say
Careful identification and vetting of spokespersons, training on FDA regulations, and development of content that conveys the typical patient experience are keys to successful and compliant influencer campaigns, advertising, legal and regulatory experts told a recent DIA conference.
Keeping Track: Gilead Gets CRL For Bulevirtide, CytoDyn Withdraws Leronlimab; Eye and CNS Drug Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
PureTech’s Failure Leaves Long COVID Treatment Hopes Looking Thin
PureTech’s LYT-100 has failed to show benefit over placebo in long COVID, and raised doubts about how treatable the condition is – in contrast to the drug’s other potential use in idiopathic pulmonary fibrosis.
Physician Communication That Combined Results Of Unrelated Studies Gets Rebuke From US FDA
Althera’s misleading claims about its cholesterol drug Roszet is based on a ‘scientifically unsound analysis,’ OPDP tells company. FDA says studies cited in the pamphlet for doctors do not support claims regarding the magnitude of treatment effect.
- Large Molecule
- Other Names / Subsidiaries
- Advanced Genetic Technologies INC.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.